In the second part of our cell therapy series this week, we take on three quite different issues.
These include the following:
- A new dual CAR in development
- Where cell therapy may be heading and how to address the limitations
- The Cellectis CS–1/SLAMF7 clinical hold
Not all CAR T cell therapies are going to end up as a bridge to transplant – some of them are clearly intended to be more efficacious than their predecessors – but along the way the trials, tribulations and clinical challenges continue apace.
These are all meaty topics to consider, so with out much further ado, let’s roll…
To learn more from our oncology analysis and get a heads up on insights and commentary emerging from recent events, subscribers can log-in or you can click to gain access to BSB Premium Content.
This is an extended update that I’ve been planning to write for some time, however, there was always some shiny new clinical data to highlight and discuss so it sadly stayed on the backburner!
Is the sun rising on CAR-T cell threats from the East?
Over the next few weeks, we will post some meaty reviews on various topics pertinent to cancer research R&D. They might involve a particular tumour type that is seeing extensive developments, an important or difficult target, or even a particular category approach, for example.
In the first of this new mini-series, we take a look at the CAR-T cell therapy niche and highlight some important new developments that are well worth watching out for.
Things are a-changin’ very rapidly here, including numerous R&D threats from the east (China) so it’s a good opportunity to take stock and look forward.
Here we go – hold on to your hats…
To learn more from our latest analysis and get a heads up on our oncology insights, subscribers can log-in or you can click to gain access to BSB Premium Content.